Dynavax Soars on Positive Late Stage Results

Health and Healthcare

Published: January 7, 2016 1:55 pm

Last Updated: January 13, 2020 3:18 pm

Dynavax Technologies Corp. (NASDAQ: DVAX) led the bulls on Thursday with positive results from a late stage clinical trial, on another consecutive down day for the broad markets. The reported preliminary top-line results from HBV-23, a Phase 3 trial of the safety and immunogenicity of its investigational hepatitis B vaccine, Heplisav-B, compared with a currently marketed vaccine, Engerix-B.

Heplisav-B participants received two doses, at zero and one month, and Engerix-B participants received three doses, at zero, one and six months. Both co-primary endpoints were met. The rates of clinically significant adverse events were consistent with randomization and similar to rates in prior trials, and Heplisav-B provided a statistically significant higher rate of seroprotection than Engerix-B in diabetic participants and in all participants as a group.

Eddie Gray, CEO of Dynavax, commented:

We are delighted to report these topline results from HBV-23 and confirm our intention to resubmit the HEPLISAV-B BLA by the end of March. These results support our belief that HEPLISAV-B, if approved, could offer benefits to adults at risk for hepatitis B, particularly given that these significant differences in seroprotection were demonstrated in a controlled setting, where compliance is optimized.

Robert Janssen, chief medical officer, added:

These topline results are consistent with our expectations. With regard to the principal safety focus, Adverse Events of Special Interest, the results reflect a distribution consistent with randomization. To see such statistically significant differences in immunogenicity so consistently and across all groups and patient subsets, confirms the potential of HEPLISAV-B for people in need of protection.

Dynavax plans to resubmit the Heplisav-B Biologics License Application (BLA) at the end of the first quarter of 2016 and anticipates a six-month review by the FDA.

Shares of Dynavax were trading up 26.3% at $26.75 on Thursday, with a consensus analyst price target of $46.25 and a 52-week trading range of $15.80 to $32.49.

Are You Still Paying With a Debit Card?

The average American spends $17,274 on debit cards a year, and it’s a HUGE mistake. First, debit cards don’t have the same fraud protections as credit cards. Once your money is gone, it’s gone. But more importantly you can actually get something back from this spending every time you swipe.

Issuers are handing out wild bonuses right now. With some you can earn up to 5% back on every purchase. That’s like getting a 5% discount on everything you buy!

Our top pick is kind of hard to imagine. Not only does it pay up to 5% back, it also includes a $200 cash back reward in the first six months, a 0% intro APR, and…. $0 annual fee. It’s quite literally free money for any one that uses a card regularly. Click here to learn more!

Flywheel Publishing has partnered with CardRatings to provide coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.